Zydus Lifesciences Limited has informed the Exchange about General Updates

Listed-company acquisitionOpen offer triggeredStrategic Transactions View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹867.25

prior close

₹889.80

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+2.3%-1.0% vs market

Pharmaceuticals peers, median of 146sector+2.6%-1.2% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty 100 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-1.1

15m

-1.2

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+2.3-1.0+2.6-1.2

Next day

-4.8+2.9-7.6+3.4-8.1

-4.2+4.5-8.7+4.0-8.2

-2.5+5.8-8.3+4.8-7.3

-1.8+6.0-7.8+5.3-7.1

-0.0+6.7-6.7+5.8-5.9

-1.0+5.2-6.2+3.6-4.5

15d

-0.1+5.6-5.7+0.5-0.6

+4.1+9.4-5.3+4.7-0.6

+12.1+9.4+2.7+8.8+3.3

+11.7+10.6+1.1+10.5+1.2

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences has incorporated a wholly owned subsidiary named Zydus MedTech (France) SAS on April 10, 2025, through its existing wholly owned subsidiary Zydus MedTech Private Limited. This new French entity has been set up specifically to acquire equity shares of Amplitude Surgical SA, the French target company. The acquisition was originally announced on March 11, 2025, for an 85.6% stake at Euro 6.25 per share, totalling Euro 256.8 million, with a planned mandatory cash tender offer for the remaining shares and a potential squeeze-out and delisting. The newly incorporated entity has a paid-up capital of just Euro 100 and has not yet commenced business operations, as it has been set up purely as an investment vehicle for the deal.

Likely market impact

This is a procedural/structural step that facilitates the previously announced acquisition of Amplitude Surgical, helping with regulatory and tax efficiency in France. It signals continued progress toward closing the deal but does not change the deal economics; shareholders should watch for completion of the block acquisition and the subsequent tender offer.